$RGC Healthcare Stock for your watchlist - Using
Post# of 24955
(Total Views: 185)
Posted On: 11/26/2022 9:58:07 AM
$RGC Healthcare Stock for your watchlist - Using Traditional Chinese Medicine (TCM) Method
Regencell Bioscience Holdings Limited (Nasdaq: RGC) a bioscience company focusing on treatment using Traditional Chinese Medicine (”TCM”) on neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19. The company is mainly focusing on both R&D of these treatments and also commercialization of the medicine once conclusive results are met.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Regencell Bioscience Holdings Limited (Nasdaq: RGC) a bioscience company focusing on treatment using Traditional Chinese Medicine (”TCM”) on neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19. The company is mainly focusing on both R&D of these treatments and also commercialization of the medicine once conclusive results are met.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
(0)
(0)Scroll down for more posts ▼